Nuevolution AB announced completion of positive data for NUE20798 from an atopic dermatitis (eczema) mouse model showing reduction of both disease - and clinical biomarker levels. No negative effect was observed on the blood platelet count (so-called thrombocytopenia) when using Nuevolution's selective bromodomain inhibitor NUE20798. Nuevolution has developed potent and selective compounds, with a benign safety profile targeting the first bromodomain of the BET family of proteins and recently nominated NUE20798 as its development candidate. The present model and collective data validate a potent effect of NUE20798 on the CCL2 chemokine biomarker relevant across atopic dermatitis, fibrotic diseases including potentially cancer fibrosis. Previous data support a potent suppression by NUE20798 of the CCL2 chemokine production from stimulated human skin cells (keratinocytes) mimicking aspects of atopic dermatitis. Based on the positive in vitro data on keratinocytes, Nuevolution conducted this in vivo testing of NUE20798 for effect in the Calcipotriol-induced atopic dermatitis mouse model. Following 11 days of oral dosing with NUE20798, reduction of disease level and potent suppression of the CCL2 disease biomarker was observed for all three dosing arms [3, 10 and 30 mg/kg, twice daily]. Further safety evaluation in the study based on blood platelet count, a well-established safety liability for non-selective BET inhibitors, showed no adverse effect on platelet numbers even at the highest dose of NUE20798. More than 13 million (diagnosed) patients world-wide suffer from atopic dermatitis and the market is forecasted to grow to USD 9.5 billion in 2020. The market opportunity in the treatment of fibrotic diseases, like idiopathic pulmonary fibrosis (IPF) as well as scleroderma (SSc), is also highly attractive. The IPF market is expected to grow with approximately 7.5% to USD 3.5 bn. in 2024, whereas a market growth of approximately 5% is expected in SSc.